IL22 and lung carcinoma: The PI3Kγ inhibitor AS-605240, another top candidate, was found to suppress lung carcinoma inflammation and the secretion of pro-inflammatory cytokines (e.g. IL-17, IFN-γ, IL-22, GM-CSF, IL-6, IL-4, and IL-13) (40–43).